Moran introduces bipartisan Cancer Drug Parity Act
Bipartisan legislation recently offered by U.S. Sen. Jerry Moran (R-KS) would prevent insurers from charging cancer patients higher copayments for oral medications than for chemotherapy medicine delivered intravenously.
“Access to new treatments, therapies, and cures will help save lives,” said Sen. Moran.
The Cancer Drug Parity Act, S. 2039, which Sen. Moran signed on to as the lead original cosponsor alongside bill sponsor U.S. Sen. Tina Smith (D-MN), would amend the Employee Retirement Income Security Act (ERISA) of 1974 to require a group health plan, or health insurance coverage offered in connection with such a plan, to allow cost-sharing for oral anti-cancer drugs on terms no less favorable than the cost-sharing provided for anti-cancer medications administered by a healthcare provider, according to the congressional record bill summary.